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Abstract
Background: Malaria remains a disease of devastating global impact, killing more than 800,000 people every year—the vast
majority being children under the age of 5. While effective therapies are available, if malaria is to be eradicated a broader
range of small molecule therapeutics that are able to target the liver and the transmissible sexual stages are required. These
new medicines are needed both to meet the challenge of malaria eradication and to circumvent resistance.
Methods and Findings: Little is known about the wider stage-specific activities of current antimalarials that were primarily
designed to alleviate symptoms of malaria in the blood stage. To overcome this critical gap, we developed assays to
measure activity of antimalarials against all life stages of malaria parasites, using a diverse set of human and nonhuman
parasite species, including male gamete production (exflagellation) in Plasmodium falciparum, ookinete development in P.
berghei, oocyst development in P. berghei and P. falciparum, and the liver stage of P. yoelii. We then compared 50 current
and experimental antimalarials in these assays. We show that endoperoxides such as OZ439, a stable synthetic molecule
currently in clinical phase IIa trials, are strong inhibitors of gametocyte maturation/gamete formation and impact
sporogony; lumefantrine impairs development in the vector; and NPC-1161B, a new 8-aminoquinoline, inhibits sporogony.
Conclusions: These data enable objective comparisons of the strengths and weaknesses of each chemical class at targeting
each stage of the lifecycle. Noting that the activities of many compounds lie within achievable blood concentrations, these
results offer an invaluable guide to decisions regarding which drugs to combine in the next-generation of antimalarial
drugs. This study might reveal the potential of life-cycle–wide analyses of drugs for other pathogens with complex life
cycles.
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Introduction
Malaria remains one of the most widespread infectious diseases
of our time. The latest estimates reveal that ,250 million people
are infected with malaria across the globe, of whom ,800,000 die
every year [1], the vast majority being young children. In 2007,
the malaria eradication agenda was adopted by many researchers
in the antimalarial community and target product profiles for new
antimalarial medicines were defined [2]. Most available antima-
larials were designed to target the pathogenic blood stages in
humans and to address the constant threat of drug resistance [3].
However, to meet the objective of malaria eradication, medicines
that block parasite transmission [4] and eliminate the asymptom-
atic and sometimes cryptic hepatic forms also need to be
developed. The bottleneck populations of liver and sexual stage
parasites [5] represent potential pathogen vulnerabilities that
could be targeted by small molecules; the first such bottleneck is at
the liver stage. Within minutes of being released by the bite of an
infected female Anopheles mosquito, Plasmodium sporozoites reach
the mammalian liver, where they invade hepatocytes and either lie
dormant or develop over several days, eventually forming the
schizonts that are the prelude to a blood stage infection [6].
Molecules that efficiently target the parasite stages in the liver
would offer protection from infection and could theoretically
eliminate the cryptic hypnozoite (dormant parasite) infection
reservoirs formed by P. vivax and P. ovale. Because only 100 or so
sporozoites may be introduced by a bite, there are likely to be
many orders of magnitude fewer parasites at this stage than in an
active blood stage infection, reducing the possibility of resistance
arising. A second bottleneck occurs during sexual development. At
each round of schizogony ,1% of merozoites differentiate into
gametocytes [7], and it is these developmentally arrested cells that
are transmitted to the mosquito. Mature gametocytes are sexually
dimorphic, forming microgametocytes and macrogametocytes that
escape the red blood cell (RBC) and produce male and female
gametes in the blood meal of the mosquito by processes known as
exflagellation [8] and activation, respectively. Following fertiliza-
tion the zygote differentiates into a motile and invasive ookinete
within which the briefly diploid genome undergoes meiosis. These
processes occur within an environment almost totally derived from
host blood, which can therefore provide a novel and ideal conduit
for the delivery of drugs to inhibit parasite transmission to the
mosquito. Having crossed the mosquito midgut wall [9], the very
few surviving ookinetes differentiate into oocysts, which undergo
endomitosis, eventually producing thousands of daughter sporo-
zoites. The sporozoites migrate from the midgut of the mosquito to
its salivary glands where the lifecycle begins again.
Given that it would be highly desirable for candidate drugs to
have activity against hepatic and sexual forms of the malarial
parasite, it is surprising that few clinical trials, to date, have
examined whether gametocyte carriage can be reduced following
drug treatment. The only drugs found to be effective at reducing
gametocyte carriage include artemisinin [10], artemisinin combi-
nation therapies (ACTs) [11,12], methylene blue [13], and
primaquine [12,14]. Additionally, few studies have investigated
the impact of drugs on the transmission of parasites from human
blood to the mosquito vector [15–18], nor have many been
designed to evaluate antihepatic stage activity. In the context of
malaria eradication these gaps in our understanding of the full
potential of the drug armoury are problematic.
Here we report the development of a series of novel assays
against liver, sexual blood, and mosquito stages of the malaria
parasite, using both drug-susceptible and drug-resistant parasite
strains. We applied these assays to the current portfolio of
schizonticidal compounds, consisting of 50 anti-infectives currently
in use or under development..
Methods
Ethics Statement
All work involving laboratory animals for the host-to-mosquito
transmission studies was performed in accordance with the
European Union (EU) regulations ‘‘EU Directive 86/609/EEC’’
and within the regulations of the United Kingdom Animals
(Scientific Procedures) Act 1986, sanctioned by UK Home Office
Licence PLL70/6347 awarded in January 2008. Protocol design
and implementation was guided by the principle of the three Rs
(reduction, refinement, and replacement) and are of mild-to-
moderate severity. Protocols are regularly reviewed and revised
following approval by the Imperial College Ethics Review
Committee.
Parasite Maintenance
P. berghei parasites constitutively expressing GFP (PbGFPcon)
[19–21] were routinely maintained as described previously [22].
Only blood showing exflagellating parasites was used in the
transmission assays.
P. falciparum NF54 strain parasites were maintained in culture as
described previously [23]. Gametocyte cultures were produced as
described [24].
P. falciparum In Vitro Antimalarial Activity
In vitro antimalarial activity was measured using the [3H]-
hypoxanthine incorporation assay [25] with various strains of P.
falciparum obtained from MR4. Results were expressed as the
concentration resulting in 50% inhibition (IC50).
P. falciparum Exflagellation Assay
Compounds were added to mature gametocyte of drug-sensitive
P. falciparum cultures that showed the ability to exflagellate. After
24 h, exflagellation was triggered by a temperature decrease to
,21uC and observed 20 min later under the microscope. Highly
motile exflagellation centres were recorded for ,50–150 adjacent
fields of view and reported per 10,000 RBCs.
P. berghei Ookinete Development Assay – Slide Method
Compounds and P. berghei gametocyte-infected blood were
dispensed in a 96-well plate containing ookinete medium [26].
After 24 h at 19uC, Giemsa-stained ookinetes were counted under
the microscope (640) as previously described [27,28].
Standard Membrane Feed Assay – P. berghei
Membrane feeds were performed as described previously [22].
Briefly, PbGFPcon-infected mouse blood was mixed with
compounds, immediately placed into membrane feeders (39uC)
and offered for 30 min to 80–100 overnight-starved A. stephensi
(SDA 500 strain). After 7–9 d at 19uC/80%RH, mosquito midguts
were dissected out. Midguts were fixed with paraformaldehyde
and oocyst number was determined microscopically by semi-
automated analysis as previously described [29].
Standard Membrane Feed Assay – P. falciparum
Gametocyte cultures were produced according to the same
protocol as the Pf exflagellation assay. Pooled gametocyte cultures
[30] were evenly divided between compounds in fresh medium
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and incubated at 37uC for 24 h. The parasite pellets were then
resuspended in fresh RBCs and human serum treated with the
compounds to a 50% haematocrit and immediately fed to
mosquitoes as described above and then maintained at 27uC/
60%RH for 10–12 d before dissection and counting.
Liver Stage Assay
7.56103 HepG2 cells in 50 ml of medium (1.56105 cells/ml)
were seeded in 384 well plates (Aurora 384 IQ-EB Black/Clear
Plates) 20–26 h prior to the actual infection [31]. 2 h prior to
infection, 50 nl of compound in DMSO (0.1% final DMSO
concentration per well) were transferred with a PinTool (GNF
Systems) into the assay plates (10 mM final concentration). P. yoelii
sporozoites were freshly dissected from infected A. stephensi
mosquito salivary glands and filtered twice with a 40-mm strainer.
The HepG2 cells were then infected with 86103 sporozoites per
well. After infection and 1-h incubation at 37uC, the cultures were
washed, new media and compound added, and further incubated
with 5-fold increased concentration of penicillin/streptomycin for
48 h at 37uC before exoerythrocytic forms (EEFs) quantification of
infected cells by immunofluorescence.
EEF immunofluorescence quantification. After washing
with 16PBS and fixation of the cells with 4% paraformaldehyde
solution (EMS), membranes were permeabilised with 0.5% Triton-
X-100 (Thermo Fisher Scientific) and EEFs were stained using a
mouse polyclonal serum raised against the Plasmodium heat shock
protein 70 (HSP70), an Alexa goat antimouse IgG, Fca-specific
DyLight 649 secondary antibody (Invitrogen), and the Hoechst
33342 nucleic acid dye (Invitrogen). Stained EEFs were then
quantified using the Opera Confocal High Content Screening
system (PerkinElmer). Images were collected using a 206
magnification at a binning of 2 using a 365 Xeon arc lamp
illumination to detect the nuclei and 635-nm laser line to excite
DyLight649.
High-content imaging of infected HepG2-CD81 cells was
performed as described in Meister et al. [31]. Wells were analysed
using a custom Acapella (PerkinElmer) script parameterized for
this assay. In brief, images from fields inside the well were first
discarded as out of focus when the intensity in the nuclear area was
too low. Then hepatic cells were counted by detecting the nuclei
labelled with Hoechst 33342 and parasites were segmented using
the HSP70 immuno-labelling. Morphology-based (e.g., area,
roundness) and intensity-based features were calculated for each
object detected including the hepatocyte nuclei and the parasites.
Parasitemia was set as the ratio between parasite number (Alexa
fluor positive) and the hepatocyte nuclei count, determined at the
same time.
Results
Schizonticidal Activities of Compounds against Strains of
P. falciparum with Known Drug Resistance Markers
A collection containing all antimalarials approved for use in
humans and those in clinical development, anti-infectives, and
other controls (Figure 1) was profiled simultaneously on asexual
blood stage parasites in a standardized growth inhibition assay
(GIA) [25] using seven strains of P. falciparum exhibiting diversity in
the molecular causes of resistance and geographical origins (Table
S1). The half-maximal inhibitory concentrations (IC50) were
determined for each molecule (Table S2). Known mutations in
pfcrt, pfmdr1, pfdhfr, and pfdhps correlated with a loss of potency of at
least 10-fold for the relevant drugs. As expected the 4-
aminoquinolines (4-AQs) chloroquine and hydroxychloroquine
showed a 6–100-fold reduction in potency against all drug-
resistant strains containing the mutated chloroquine transporter
(PfCRT) (Figure 2B). Amodiaquine, tert-butyl-isoquine pyronar-
idine, piperaquine, and naphthoquine were potent against all
parasite lines (IC50 = 2–10 nM), as were the endoperoxides
including the natural (artemisinin), the semi-synthetic (artesunate),
or the fully synthetic peroxides (ozonides), all with IC50 values of
1–15 nM (Figure 2A).
Compared to the 4-AQs, the 8-AQs (8-AQs) primaquine,
diethylprimaquine, and bulaquine were less potent (IC50 = 0.5–
2.5 mM) (Figure 2C) against both drug-resistant and -sensitive
strains. Tafenoquine and NPC-1161B exhibited IC50 values in the
500-nM range against NF54 and in the 50-nM range against 7G8.
IC50 values of both racemic mefloquine and the +RS isomer were
below 10 nM. Halofantrine and lumefantrine displayed potencies
below 4 nM against the sensitive strains NF54 and D6 and in the
case of halofantrine, 0.3 nM against the multi–drug-resistant
strains K1, W2, and 7G8. Resistance to pyrimethamine was
verified in all drug-resistant strains (Figure 2D). Atovaquone a
drug active in the subnanomolar range against P. falciparum blood
stages showed at most a 10-fold difference in potency between the
strains D6 and V1/S. In contrast, a $100-fold loss of potency was
observed for cycloguanil between sensitive and resistant strains.
The antibiotics azithromycin and trimethoprim, protein synthesis
inhibitors, and other molecules such as dehydroepiandrosterone
(DHEA), riboflavin, doxycyclin, and the prodrug proguanil
showed IC50 values in the 1–10-mM range with no major
differences between strains.
The Identification of Drugs That Additionally Block
Transmission from Human Host to Mosquito Vector
Eradicating malaria will require medicines that prevent
transmission of the parasite between humans and mosquitoes.
Potentially the severe population bottleneck experienced as the
parasite progresses from the mature gametocyte in the human host
through gametogenesis and fertilization in the mosquito blood
meal to the oocyst in the mosquito haemocoele offers the most
vulnerable target for intervention. We developed assays for each of
these events (Figure 3A). To integrate both the early sexual stages
(gametocyte maturation and gametogenesis) and the late vector
stage (sporogony) into the drug-testing cascade, we measured the
exflagellation of male gametes in vitro (P. falciparum), ookinete
formation in vitro (P.berghei), and the production of oocysts in A.
stephensi (P. berghei and P. falciparum). Of these assays, we found
analysis of P. berghei ookinete production in vitro was the most
robust approach to identify molecules potentially targeting the
early development of Plasmodium parasites in the mosquito. Forty-
six molecules were tested at a concentration of 10 mM (Figure 3B).
The most potent molecules were cycloheximide (blood stage IC50
of 25 nM) and atovaquone (IC50 = 65 nM). Thiostrepton
(IC50 = 8 mM) and pyronaridine (IC50 = 6 mM) were less potent
(Figure 3C). The latter two molecules and pyrimethamine also
inhibited P. falciparum exflagellation by more than 80%, as did
Figure 1. The main classes of antimalarials. The chemical structures of all the main classes of antimalarials and other therapeutic and control
molecules are assembled according to either the chemical classes they belong to (endoperoxides, 4- and 8- AQs, amino-alcohols) or their function
(antifolate, antibiotics), or both (e.g., sulfonamides, a chemical class of antibiotic used in combined antimalarial therapies). The colour code associated
with each class is consistent in all the figures in this report.
doi:10.1371/journal.pmed.1001169.g001
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Figure 2. The potencies of selected antimalarials against asexual blood stages. Main classes of antimalarials were tested against the blood
stage of seven Plasmodium falciparum strains in the [3H]hypoxanthine incorporation assay as described in Vennerstrom et al. [25]. The strains tested
here (obtained from MR4) were two drug-sensitive strains NF54 and D6 and five drug-resistant strains: K1, resistant to chloroquine (CQ) and
pyrimethamine (PYR), origin Thailand, carries mutations in genes pfmdr1, pfcrt, pfdhfr, pfdhps; W2, resistant to CQ, PYR, quinine, cycloguanil, and
sulfadoxine, origin Vietnam; 7G8, resistant to CQ and PYR, origin Brazil; TM90C2A, resistant to CQ, PYR, and MFQ, origin Thailand; and V1/S, resistant
to CQ, PYR and cycloguanil, origin Vietnam. Results are expressed as the concentration resulting in 50% growth inhibition (IC50).Values are means of
$3 independent experiments. (A) Endoperoxides. (B) 4-AQs. (C) 8-AQs and amino alcohols. (D) Antifolates, antibiotics, and others.
doi:10.1371/journal.pmed.1001169.g002
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Figure 3. The transmission-blocking potential of selected antimalarials in three bioassays that cover different phases of Plasmodium
vector stage development. (A) Assays examined exflagellation (P. falciparum), ookinete formation (P. berghei), or oocyst formation (P. falciparum).
All antimalarials were screened at 10 mM. (B) The biological content of the in vitro P. berghei ookinete assay spans gamete formation, fertilization,
zygote development, and ookinete formation. Ookinete formation was insensitive to most of the antimalarials tested. Atovaquone, cycloheximide,
Effect of Key Antimalarials on Parasite Life Cycle
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sulfamethoxazole and mefloquine (+RS). While displaying insig-
nificant activity in the P. berghei ookinete formation assay
(Figure 3C), all endoperoxides, with the sole exception of
artemether, inhibited P. falciparum exflagellation by .65%
(Figure 3D). Similarly all 4-AQs inhibited this event by .60%,
with the exception of hydroxychloroquine and chloroquine, which
enhanced exflagellation by at least 20% [16].
While recognising that the drugs being evaluated are not subject
to metabolic degradation/activation by the mammalian hosts,
among the 8-AQs, NPC-1161B and diethylprimaquine inhibited
exflagellation by more than 70%. In marked contrast primaquine
and the amino alcohol halofantrine unexpectedly stimulated
exflagellation by 15% and 45%, respectively. All main chemical
classes were then evaluated specifically against the vector stages by
analysing the inhibition of P. berghei oocyst formation in vivo. Only
NPC-1161B and lumefantrine exhibited .90% inhibition when
tested at 10 mM (Figure S1). The transmission-blocking potential
of molecules that were active against exflagellation and/or P.
berghei sporogony was then assessed against the production of P.
falciparum oocysts, which is the most difficult and lowest
throughput, yet highest content analysis by encompassing all
vector stages from gametocyte uptake to sporogony (see Figure 3A).
In this assay, most endoperoxides inhibited oocyst production by
.75%; NPC-1161B and mefloquine (+RS) totally blocked
transmission at this stage (Figure 3E). Strikingly, the Coartem
component, lumefantrine, and halofantrine impaired sporogony in
both P. berghei and P. falciparum, while both mediated only
moderate or no inhibition of exflagellation. This finding suggests
that these molecules might act specifically on oocysts and not on
gametogenesis, a behaviour that could be relevant to transmission
reduction in the field given the long half-life of these molecules. As
exflagellation is a component process of development within the
gut of the mosquito in the P. falciparum oocyst assay (see Figure S2),
these results, not unexpectedly, show at least partial concordance
with the P. falciparum exflagellation assay.
The Identification of Drugs That Suppress Transmission
from the Mosquito to the Human Host
When an infected mosquito bites a host, ,100 sporozoites may
be injected into the dermis from where they rapidly invade liver
cells [32,33]. This infective step represents the second bottleneck
during transmission and therefore another potentially vulnerable
point for intervention. In the absence of a practical liver stage
assay measuring the formation of P. falciparum/P. vivax liver
schizonts, an equivalent assay was developed in P. yoelii and used to
assess the activity of the collection of molecules against this specific
stage. Specifically, P. yoelii sporozoites were dissected from the
salivary glands of infected mosquitoes and were allowed to invade
human hepatocarcinoma cells expressing the CD81 protein. The
development of the liver schizonts was monitored by immunoflu-
orescence staining using an HSP70 antibody specific to the
parasite (Figure 4A). As only 1% of the hepatocytes are infected in
these circumstances, high content imaging was used to quantify
growth inhibition of parasite schizonts (Figure 4B, 4D). Quanti-
fication of the total immunofluorescence per well is shown in
Figure 4C. Dose response analysis using serially diluted com-
pounds showed that cycloguanil, pyrimethamine, P218, and
atovaquone all displayed IC50 values below 10 nM (Figure 4B,
4D). Methylene blue and artemisone demonstrated IC50 values of
,100 nM. All endoperoxides tested in this assay, except
artemisinin, exhibited IC50 values ,3 mM, as did amodiaquine,
AQ-13, pyronaridine, and naphthoquine. Of the 8-AQs, NPC-
1161B was the only drug active in the submicromolar range
against P. yoelii liver stages. Deferoxamine, thiostrepton, trimeth-
oprim, and quinidine exhibited submicromolar potencies. Cyclo-
heximide and thiostrepton, although showing IC50 values below
200 nM (Table 1), retarded the growth of HepG2-CD81 cells.
Discussion
Modes of Action of Major Classes of Antimalarials beyond
the Asexual Blood Stage
The IC50 values of the known schizonticides against the asexual
blood stages determined in this study correlate well with those
reported in recent work examining 185 culture-adapted parasite
strain lines treated with seven antimalarials [34].
Many schizonticidal drugs are hypothesised to interfere with
haemoglobin metabolism. Our study shows that some of these
drugs have activities against parasite stages that lack haemoglobin
metabolism, e.g., the liver schizont, mature gametocyte, and
sporogonic stages. This finding raises interesting questions about
the mode(s) of action of these compounds beyond the asexual
blood stage and our understanding of parasite metabolism. For
example, natural, semi-synthetic and synthetic endoperoxides
(artemisinin, DHA, artesunate, OZ277, and OZ439) are not only
fast-acting molecules [35], but are among the most potent
antimalarials currently used against the asexual blood stages
[36]. They are thought to act by alkylating haem and other vital
biomolecules [37,38] (e.g., Pf TCTP) [39], and degrading
phospholipids in parasite membranes [40]. The latter mechanism
would be expected to have a major impact on all vegetative/
replicating stages of Plasmodium’s life cycle, e.g., asexual blood
stage, liver schizont, oocyst, and microgametogenesis; and this is
consistent with our results showing endoperoxide activity directly
or indirectly against P. falciparum exflagellation, oocyst production,
and P. yoelii liver schizont development. The lesser impact of this
chemical class on ookinete and oocyst development in P. berghei
might suggest species to species differences. It is also worth noting
that because drugs are applied in human blood containing mature
gametocytes prior to triggering exflagellation, inhibition of
exflagellation by these molecules could be the direct consequence
of a gametocytocidal property rather than solely a specific effect on
gamete formation. Our data confirmed that 4-AQs are highly
active against asexual blood-stage parasites in vitro, while the 8-
AQs are not, indicating that subtle changes in the AQ core
structure can result in major differences in the mode of action of
pyronaridine, pyrimethamine, and thiostrepton all strongly inhibited ookinete formation (p,0.03 by Student’s t-test), while tafenoquine, cis-
mirincamycin, and fosmidomycin gave an enhancement of ookinete formation that was not statistically significant. (C) The medium throughput
fluorescent ookinete assay determined IC50 values for pyronaridine, thiostrepton, cycloheximide, and atovaquone of 6 mM, 8 mM, 25 nM, and 65 nM,
respectively. (D) The in vitro P. falciparum exflagellation assay exposes mature gametocytes to antimalarials for 24 h before triggering exflagellation.
16 out of 29 antimalarials tested, including all but one of the endoperoxides and 4-AQs, showed a statistically significant .50% inhibition of
exflagellation (p,0.05). Pyronaridine, tert-butyl isoquine, NPC-1161B, OZ277, and cycloheximide all inhibited exflagellation totally at 10 mM. All
experiments in triplicate. (E) The in vivo P. falciparum oocyst assay differs from the P. berghei oocyst assay in that mature gametocytes were exposed
to the antimalarials in culture for 24 h before feeding to mosquitoes. The endoperoxides all strongly reduced transmission. NPC1161-B, lumefantrine,
halofantrine, and mefloquine +RS isomer were also active. (n= 4–61 observations; average 6 standard error of the mean [SEM]).
doi:10.1371/journal.pmed.1001169.g003
Effect of Key Antimalarials on Parasite Life Cycle
PLoS Medicine | www.plosmedicine.org 7 February 2012 | Volume 9 | Issue 2 | e1001169
Figure 4. Validation and results of anti-infectives tested against P. yoelii liver stage parasites. (A) Opera-generated images from a time
point experiment using a 206objective lens. P. yoelii parasites (red) were visualized using a mouse polyclonal HSP70 antibody, and the HepG2 cells
(green) were stained with Hoechst 33342 nucleic acid dye. Median parasite areas for the 15-h, 27-h, and 51-h time points were calculated as 16, 52,
and 158 mm2, respectively, using a custom Acapella script. (B) A dose response plot with atovaquone from data generated from the Opera imaging
system. The median areas of compound-treated parasites were compared to untreated DMSO controls to determine the degree of inhibition. The IC50
value of atovaquone is 22 nM. (C) From the Acumen eX3 imaging system, a 384-well heat map plate image of P.yoelii fluorescence intensities from a
dose response experiment with the most active anti-infectives. The three wells at the top left corner were not infected with sporozoites and served as
a negative control. Wells were treated with a 1:3 dilution of compounds starting at 30 mM (0.1% DMSO). In the experiments where the highest
compound concentration tested was 10 mM, the entry is labelled 10. Compounds used are: naphthoquine (naph.), pyrimethamine (pyri.),
trimethoprim (trim.), deferoxamine (defe.), artemisone (artem.), atovaquone (ato.), artesunate (artes.), cycloguanil (cyclo.), methylene blue (met. bl.),
quinidine (quin.), dihydroartemisinin (DHA). Triangles represent the dilution steps of the drugs as described above. Stars designate the three wells
with no sporozoite. (D) IC50 results from a compound dose response experiment performed in a 384-well plate format. Results were generated from
the Opera using median parasite area to determine level of inhibition.
doi:10.1371/journal.pmed.1001169.g004
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some key antimalarials, although our data cannot address the
possibility that the 8-AQ metabolites could be more active.
Interestingly, molecules such as amodiaquine, pyronaridine, and
tert-butyl-isoquine that target inter alia haem degradation also
inhibited P. falciparum exflagellation. We are unaware of any prior
data suggesting that haem degradation is essential to male gamete
formation. This finding raises fascinating questions as to whether
their modes of action in the mosquito blood meal are targeting the
same, or different, molecular mechanisms. One working hypoth-
esis could be that the major targets mediating the effect of these
molecules in the sexual stages might also contribute to the effect
seen in the asexual stages.
The 8-AQs are known to be active on the relapsing
‘‘hypnozoite’’ liver form of P. vivax following metabolic activation
of the parent compound by liver enzymes [41]. In our assay
where we do not anticipate any metabolism of any drugs, we note
that the 8-AQ NPC-1161B was additionally shown to inhibit
exflagellation in vitro and oocyst production in the mosquito
vector. This result suggests either that NPC-1161B does not
require metabolic activation or the drug exhibits poly-pharma-
cology by acting through another metabolite-independent
mechanism. The antifolates P218 and pyrimethamine were
found to be potent against rapidly replicating blood and liver
stages and much less so against early vector stages, observations
consistent with the essential role of the folate pathway in DNA
synthesis [42].
When mature gametocytes are ingested, exflagellation is
activated by a reduction in temperature and the presence of
xanthurenic acid in the gut of the mosquito [43]. Inhibition of
exflagellation by thiostrepton and cycloheximide is consistent
with the observation that protein synthesis is a key component of
these dramatic morphological changes [27], and all vegetative
stages in the life cycle. Similarly our data confirm previous studies
[44–46] showing the electron transport chain can be efficiently
targeted by atovaquone in both the vector and the liver. For such
stage-transcendent pathways, it could be hypothesised that the
much lower parasite burden observed in the vector and the liver
would increase the probability that treatments would eliminate
infections when compared to targeting the abundant blood stage
parasites. An important consequence would be that drugs
specifically targeting the small ‘‘bottleneck’’ populations might
delay significantly the selection of drug-resistant parasites.
‘‘Management’’ of Drug Delivery to the Mosquito Blood
Meal
While both our studies and the comprehensive treatise of Peters
[47] show unequivocally that for many compounds effective
delivery into the blood meal of the mosquito can be achieved,
management of such delivery in the field is not trivial. In this
context we note that the Cmax following administration of
therapeutic doses for many antimalarials overlap the predicted
potencies of the same antimalarials determined here against early
vector stages (0.5–10 mM). For instance, in reported clinical trials,
Cmax was shown to vary from 0.1 mM to 13.9 mM for artemether
and lumefantrine administered at therapeutic doses, respectively.
In the case of new molecules such as OZ439, Cmax values obtained
in blood at relevant doses ranged between 1 and 2.5 mM (Table
S3) [48–55].
Combination Therapies
To support the eradication agenda, new combination therapies
will have to address three major issues: transmission of the
pathogen, radical cure of P. vivax malaria, and the emergence of
drug resistance. Ideally, new drug combinations should contain
both schizonticidal and transmission-blocking components. Pref-
erably fast-acting and long-lasting schizonticides would be
combined with another agent that would target the parasite either
at the sexual/vector stages, liver stage, or both. In the case of the
liver stage, a co- or post-treatment prophylaxis would be provided
as an end game scenario. From a pharmacokinetic perspective,
when considering P. falciparum, some might speculate that this
additional transmission-blocking component should be stable
enough to exert its inhibitory capacity over several days against
vector stages and/or liver schizont development to protect against
a re-infection. However, considering that the schizonticidal
component would kill both asexual blood stages and young
gametocytes (,6-d old), a second coadministered drug efficiently
eliminating mature (.6-d) gametocytes could potentially clear the
host of all parasites; i.e., a long half-life would not be required [56].
A sustained stability would however be required for drugs
targeting the parasite exclusively in the mosquito. Our study
suggests that molecules such as atovaquone that inhibit the
electron transport chain in the parasite mitochondria could be
suitable candidates, but ideally should lack delayed onset of action
and be difficult to raise resistance against [57]. To avoid triple
therapies and reduce the risk of drug resistance, dual-activity
molecules like amodiaquine, which inhibits haemoglobin digestion
in the asexual blood stages and potentially inhibits gametocyte
maturation/gamete exflagellation by a different mechanism, could
be used in combination with a second antimalarial. Such
polyvalent multistage activity has significant benefit to overall
drug impact. Our study highlights that molecules such as
amodiaquine, naphthoquine, tert-butyl-isoquine, and piperaquine
do not lose potency when tested against chloroquine resistant
strains. Therefore, to mitigate or defer the risk of drug resistance
these molecules might be proposed as potential candidates for
partnering new antimalarials such as OZ439. An important
consideration would be to favour molecules that have never been
used as monotherapy to avoid facing parasites that have previously
acquired drug resistance. NPC-1161B inhibited both exflagellation
and oocyst production; new molecules with similar properties but
devoid of haemolytic liability of the 8-AQs in glucose-6-phosphate
dehydrogenase (G6PD)–deficient patients could be interesting
candidates as specific transmission-blocking agents.
While being strong inhibitors of blood-stage parasites, some
molecules such as chloroquine reportedly enhance gametocyto-
genesis—a property that might have facilitated the spread of drug-
Table 1. The ability of key molecules to provoke growth
retardation of HepG2 cells.
Molecules IC50 Parasite (mM) IC50 HepG2 (mM) CI
Halofantrine 2.3261.35 ,5.6668.00 ,2.44
Mefloquine 1.6961.45 1.7360.60 1.02
NPC-1161B 0.7260.07 0.8460.46 1.17
OZ277 1.6961.22 7.4065.13 4.38
Pyronaridine 0.2760.13 ,0.1760.25 ,0.63
Thiostrepton 0.1860.05 0.1860.02 1.0
Cycloheximide 0.1560.01 0.9260.29 6.13
Proguanil 11.8065.19 15.4463.09 1.31
Pentamidine 2.4660.57 3.7561.10 1.52
Data were compared to the antimalarial potency of the same molecules against
the development of P. yoelii liver schizonts following infection of HepG2 cells.
CI, cytotoxicity index.
doi:10.1371/journal.pmed.1001169.t001
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resistant parasites [15,58]. The panel of assays that we applied in
this study has confirmed such ‘‘collateral’’ activity, in this case one
that could prejudice the rational implementation in any elimina-
tion/eradication strategy.
Other Human Malarias
Although many have argued for the use of drug screens using
nonhuman malarias [47], we recognize that to some, including
assays with rodent malaria species might be considered subopti-
mal. Recent observations identifying interspecific variations
include cysteine proteases in rodent plasmodia that show subtle
active site differences to those in P. falciparum, leading to questions
about the use of these models [59]. A critical role of amino acid 23
mediates activity and specificity of vinckepain-2, a papain-family
cysteine protease of rodent malaria parasites [60]. P. yoelii 17X
strain is intrinsically partially resistant to chloroquine and is
therefore a poor model for studying acquisition of P. falciparum
chloroquine resistance. Nevertheless we must recall that there are
five species of Plasmodium that infect man and their biologies are
patently different, therefore detecting drugs that may be active
against multiple species in initial screens may offer long-term
potential. Our assays provide, to our knowledge, the most
comprehensive global overview of antimalarial drug action to
date within the constraints imposed by the current state of culture
methodologies for all life stages of all mammalian malaria
parasites. Ideally, antimalarials developed against P. falciparum
would have an even broader clinical usefulness if proven to be as
effective against P. vivax [61]. The potencies of some antimalarials
against the asexual blood stage of cultivated P. falciparum and P.
vivax field isolates show a very good correlation (Table S4) [62–67].
Figure 5. Summary of the activity of the most widely used antimalarials throughout the life cycle of Plasmodium. The three main
phases, i.e., liver stage, blood stage, and vector stage, of the life cycle of Plasmodium are shown. The two key entry points leading to transmission of
the parasites from vector to host and from host to vector are indicated (green circles). Parasite forms specific to each stage are highlighted and drugs
identified as inhibitors of development of these forms are listed in boxes and coloured as described in Figure 1. Stars highlight components of the
main artemisinin combination therapies: green, coartem; red, pyramax; orange, eurartesim; blue, ASAQ.
doi:10.1371/journal.pmed.1001169.g005
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This observation suggests that most of the pathways inhibited by
antimalarials in P. falciparum are conserved and may offer valid
targets in P. vivax. Moreover, the endoperoxide OZ439, which is
currently evaluated in phase IIa clinical trials, has recently
demonstrated equivalent efficacy in the treatment of P. falciparum
and P. vivax patients (personal communication, MMV).
Drug Gaps and Future Steps
Our work has revealed previously unforeseen opportunities in the
current discovery and development pipeline for new antimalarials.
We demonstrated that drugs in the current portfolio, like
pyronaridine and atovaquone, can also target liver and sexual
stages in addition to asexual blood stages. Safe and stable drugs with
similar multistage potential are now required. Developing drugs
with long half-lives like mefloquine and chloroquine is essential to
ensure that in patient blood the exposure of these drugs will remain
above the minimum inhibitory concentration for several erythro-
cytic cycles and should ideally cover the period of gametocyte
maturation. Additionally, new chemical scaffolds (e.g., nonendoper-
oxide) with fast killing potential are needed for a ‘‘one dose cure.’’
The search for new drugs would be enhanced by the continued
development of P. falciparum and P. vivax culture systems for every
parasite life stage. It is critical to the malaria eradication agenda
that these assays are able to identify drugs, such as the 8-AQs, with
the capacity to safely eliminate P. vivax hypnozoites from the liver:
this objective will also require the implementation and validation
of in vitro and in vivo G6PD deficiency-dependent hemolysis
assays. In parallel with efforts to discover innovative drugs for
radical cure (elimination of P. vivax hypnozoites from the liver),
new molecules blocking the onward development of mature (stage
V) gametocytes are the other major priority in antimalarial
discovery. There is therefore an urgent need to develop and
validate high throughput screening assays allowing new libraries to
be tested against P. falciparum and P. vivax gametocytes/
transmission. These assays could then prioritise compounds for
examination in preclinical studies in small mammals and then in
standard membrane feeding assays (SMFA) using patient blood to
find drugs blocking transmission in the field/clinical situation.
Fields studies will remain essential to carefully examine any
correlation between activities of new molecules against stabilized
laboratory parasite strains and against field isolates.
Conclusions
For the first time, the main chemical classes of current and future
antimalarials have been profiled simultaneously in standardized
conditions against three Plasmodium species with respect to every
major cellular strategy of the malarial life cycle, e.g., vegetative
replication, dispersal, and sex (Figure 5). The present study provides
the antimalarial research community with a reference set of
methods and data, which may serve as a benchmark for newly
discovered molecules when profiled against the entire life cycle of
Plasmodium. This information might guide decisions regarding which
molecules could be optimally combined to provide the next
generation of drugs that will succeed to artemisinin combination
therapies (ACTs) [68] and support the eradication of malaria. This
comprehensive approach to drug discovery has potential utility for
targeting other pathogens with complex life cycles.
Supporting Information
Figure S1 The transmission-blocking potential of se-
lected compounds against P. berghei in standard
membrane feeding assays. All antimalarials were screened
at 10 mM in triplicate in independent experiments. The biological
content of this assay spans gamete formation through to occyst
development all within the gut of the mosquito. NPC1161-B,
lumefantrine, pyrimethamine, and cycloheximide showed most
notable transmission-blocking activity.
(TIF)
Figure S2 Comparative summary of the transmission-
blocking potential of selected compounds across vector-
stage assays. All antimalarials were screened at 10 mM. By
comparing the activities of compounds in assays covering different
biological ranges of transmission-stage biology, it is possible to
infer the stages at which antimalarial drugs are exerting their
effects. Lumefantrine was found to have little activity against
exflagellation and ookinete development but showed activity in
oocyst assays of P. berghei and P. falciparum. Endoperoxides showed
activity as early as exflagellation but not during ookinete
development, indicative of action against the mature gameto-
cyte/exflagellation. NPC1161-B showed potency in all assays
except the ookinete assay, suggesting that it may have dual actions
both in early vector-stage development and later on.
(TIF)
Table S1 The origin and reported drug resistance of P.
falciparum strains used in this study. CQ, chloroquine;
PYR, pyrimethamine; CYC, cycloganil; QUI, quinine; SUL,
sulfadoxine; MFQ, mefloquine; ATO, atovaquone.
( )
Table S2 The numerical potencies of selected antima-
larials against asexual blood stages. Data corresponding to
Figure 2, showing the numerical IC50 values of selected
antimalarial compounds against seven P. falciparum strains in the
[3H]hypoxanthine incorporation assay.
(TIF)
Table S3 A comparison of antimalarial exposure in
human blood against predicted early vector-stage po-
tency. The IC50 values of selected antimalarials in the P.
falciparum exflagellation assay was estimated using additional data
generated by screening at 1 mM (*) and compared to drug Cmax
values obtained from the literature. The in vitro assay contains
both blood and serum. Most of the cells in culture (,97%) are
uninfected RBCs. The medium that the assay is set up in is derived
from RPMI and contains 10% human serum.
(TIF)
Table S4 A comparison of the reported asexual blood
stage potencies of selected antimalarials against P.
falciparum (field and laboratory isolates) and P. vivax
(field isolates).
(TIF)
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Editors’ Summary
Background. Malaria is a life-threatening disease caused by
the Plasmodium parasite, which is transmitted to people
through the bites of infected mosquitoes. According to latest
global estimates, about 250 million people are infected with
malaria every year with roughly 800,000 deaths—most
occurring among young children living in Africa. Malaria
also causes severe morbidity in children, such as anemia, low
birth weight, and neurological problems, which compromise
the health and development of millions of children living in
malaria endemic areas. In addition to strategies that scale up
and roll out the prevention of malaria, such as country-wide
programs to provide insecticide-treating bednets, in the goal
to eradicate malaria, the global health community has
refocused efforts on the treatment of malaria, including
finding new compounds that target different stages of the
parasite life cycle as it passes from vector to host and back.
The interruption of malaria transmission worldwide is one of
the greatest challenges for the global health community. In
January 2011, this journal published a series on The Malaria
Eradication Research Agenda (malERA), which described a
set of research and development priorities, identified key
knowledge gaps and the necessary tools needed, and
introduced a draft research and development agenda for
the worldwide eradication of malaria.
Why Was This Study Done? Most currently available
antimalarial drugs primarily target the disease-causing
parasites’ stages in the human blood system. But to
eradicate malaria, new drugs that block transmission of the
parasite between the human host and the mosquito vector,
and eliminate the various stages of the parasite during its
cycle in the human body, are needed. In this laboratory
study, the researchers compared the profiles of all available
and experimental antimalarials and analyzed each drug for
activity against each specific stage in the malaria parasite’s
life cycle to provide a reference set of methods and data,
that might serve as a benchmark to help guide the malaria
research community in assessing the potential of newly
discovered antimalarials. Furthermore, this analysis could
provide insights into which chemical drug classes might
provide transmission-blocking capabilities—an essential
component of malaria eradication.
What Did the Researchers Do and Find? The researchers
used novel laboratory techniques under standardized
conditions to develop a series of novel assays to analyze
the activities of 50 antimalarial compounds (current drugs
and those under development) against three Plasmodium
species encompassing every major cellular strategy of the
malarial life cycle including drug resistant parasite strains. In
their comparative analysis, the researchers undertook a
chemical profiling approach to identify the drugs that block
transmission from the host to the mosquito vector and
additionally suppress transmission from the mosquito to the
human host.
The researchers highlighted some encouraging results; for
example, the potencies of some antimalarials against the
asexual blood stage of cultivated P. falciparum and P. vivax
isolates show a very good correlation, suggesting that most
of the pathways inhibited by antimalarials in P. falciparum
may also be valid targets in P. vivax. The researchers also
have shown that approved drugs, such as pyronaridine and
atovaquone, can target liver and sexual stages in addition to
asexual blood stages. Furthermore, the researchers found
promising results for new compounds currently in clinical
trials, such as the endoperoxide OZ439, a stable synthetic
molecule currently being studied in a phase IIa clinical trial,
which seemed to be a strong inhibitor of gametocyte
maturation and gamete formation. The new 8-aminoquino-
line, NPC-1161B, also inhibited sporogony.
What Do These Findings Mean? The results of this
analysis provide a valuable guide to help researchers decide
which drugs and compounds show most promise as potential
future antimalarial drugs for blocking the transmission of
malaria. This study could also help researchers make decisions
about which molecules could be best combined to provide
the next generation of drugs that will succeed artemisinin
compound therapy and support the eradication of malaria.
Furthermore, this comprehensive approach to drug discovery
could be applied to test drugs against other pathogens with
complex life cycles.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001169.
N The ‘‘malERA – a research agenda for malaria eradication’’
sponsored collection, published by PLoS in January 2011,
comprises 12 Review articles that discuss agendas in
malaria research and development
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